Keith A. Meister bought $3.0M of WGS
director, owner at GeneDx Holdings Corp.. 50,000 shares at an average of $60.16, traded May 14, 2025, filed May 16, 2025.
Score components
- +15RoleDirector
- +25Trade size$3.0M at market
- 0Relative to holdingsHoldings up 1.7%
- +8Price context49% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-073497, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 14, 2025 | POpen-market purchase Class A Common Stockindirect: See footnotes | +25,356 | $59.81 | $1.5M | 3,033,985 | May 16, 2025 |
| May 14, 2025 | POpen-market purchase Class A Common Stockindirect: See footnotes | +24,644 | $60.52 | $1.5M | 3,058,629 | May 16, 2025 |
Related signals
Other insiders at GeneDx Holdings Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $364k 3,728 shares | -8% | |
| 43Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.0M 10,501 shares | -8% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $108k 1,285 shares | -3% | |
| 32Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $311k 3,692 shares | -3% | |
| 20Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $31k 372 shares | -1% | |
| 44Moderate | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $555k 3,855 shares | -31% | |
| 53Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.6M 10,857 shares | -43% | |
| 32Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $202k 1,266 shares | -19% | |
| 47Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $580k 3,639 shares | -36% | |
| 29Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $61k 377 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.